entertainment -WSS

entertainment

author：fashion 2025-08-26 10:55:41 - browse：646

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： The FDA weighs the risks of candy

explore

WSS

A double vaccine crisis is endangering millions of children

Death toll from an explosion and collapse of a Paris building in June climbs to 3

FDA has safety concerns on CRISPR

The FDA weighs the risks of candy

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Biden's order seeks to regulate AI risk without stifling innovation

entertainment

entertainment

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Body of missing toddler recovered in Delaware River days after flood: Police

Hollywood unions extend contract negotiations for actors

Eli Lilly to pay $200M for Beam’s stake in gene

Medicare details structure of new drug price negotiation program

Eli Lilly to pay $200M for Beam’s stake in gene

Heart attack and stroke risk calculators need revising

Why Sanofi got shellacked over its spinoff

Medical leaders decry Supreme Court decision on affirmative action

Senate panel to vote on hospitals, PBMs, prisoner care

focus

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

As Taiwan prepares for anti

The FDA weighs the risks of candy

In new study, freeze

Biden's order seeks to regulate AI risk without stifling innovation

Why Sanofi got shellacked over its spinoff

leisure time

leisure time

explore

focus